3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Absci Corporation

Absci (ABSI) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Absci Corporation

3rd Annual Guggenheim Healthcare Innovation Conference summary

10 Nov, 2026

Pipeline strategy and ABS-201

  • Strategy has shifted from an AI drug-creation platform working with pharma partners to an owner of antibody programs; ABS-201 is the lead asset in Phase I/IIa for pattern hair loss and endometriosis.

  • ABS-201 blocks the prolactin receptor; the proposed hair-cycle effect is to move follicles from regression into active growth, while prolactin may contribute to endometriosis lesion formation and pain.

  • The target profile for pattern hair loss is 2–3 injections over six months, with potential multi-year durability after treatment ends; this remains a development goal, supported by preclinical macaque observations.

Pattern hair loss trial and readouts

  • The Phase I/IIa HEADLINE study’s SAD data, released in June, showed generally safe and tolerable results; half-life supported the intended extended dosing interval, and MAD is ongoing.

  • MAD has three planned cohorts of 49 participants at 300 mg, 600 mg and 1,200 mg, with double-blind, placebo-controlled 3:1 randomization.

  • A male-only 13-week interim analysis is expected next month; it will include target-area non-vellus hair count, total hair count and target-area hair width, with more participants from earlier than later cohorts.

  • The 13-week goal is a directionally positive hair-growth signal; the 26-week proof-of-concept readout is expected early next year, with a stronger result sought and additional patient-reported, image and other measures.

  • Results are planned by dose cohort and placebo while the study remains blinded; hair darkening or pigmentation is an exploratory potential benefit, not included in current assumptions.

  • Separate female cohorts will generate later datasets; the proposed targeted mechanism is not expected to cause unwanted hair growth, which could distinguish it from some existing options.

Endometriosis program

  • Hope Medicine’s HMI-115 data showed reduced dysmenorrhea at the high dose, viewed as proof-of-concept support; planned design refinements include a two-cycle run-in and broader geographic and ethnic diversity.

  • Phase II is planned to start in the middle of next year; the contemplated study is subject to finalization and may enroll 150 participants across 10+ countries, testing two or three doses.

  • Endometriosis endpoints are planned to include pain measures, including non-menstrual pain and dysmenorrhea; ABS-201 may also affect lesion growth and could be disease-modifying.

  • Management sees potential for a second-line role amid treatment trade-offs and estimates peak sales above $4B; endometriosis dosing is likely to differ from pattern hair loss dosing.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Absci